{
  "id": 14421403,
  "title": "Verastem Oncology prices $250 million stock offering",
  "url": "https://urgent.news/2026/10/14/verastem-oncology-prices-250-million-stock-offering",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-14T10:08:37.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/verastem-oncology-prices-250-million-stock-offering-93CH-4948580"
  },
  "original_language": "en",
  "account": "BOSTON - Verastem Oncology, a biopharmaceutical company, announced the pricing of an underwritten public offering of 30.94 million shares of common stock at $8.00 per share. The transaction is expected to gross approximately $250 million before fees. Jefferies, Guggenheim Securities, and Cantor are serving as joint book-running managers, while B. Riley Securities acts as the lead manager. The company aims to use the net proceeds to support clinical development of product candidates, including the VS-7375 program, and for general corporate purposes. The offering is conducted under a shelf registration statement effective since August 15, 2025. Verastem Oncology develops medicines for patients with cancers driven by the RAS/MAPK pathway, marketing AVMAPKI FAKZYNJA CO-PACK in the United States.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Seeking Alpha News",
        "title": "Verastem Oncology jumps after pricing $250M securities offering",
        "url": "https://urgent.news/2026/10/14/verastem-oncology-jumps-after-pricing-250m-securities-offering",
        "published": "2026-10-14T10:09:39.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}